---
title: "Understanding the Market | INNOGEN-B fell over 12% in early trading, with a cumulative decline of 25% after \"entering the market\""
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/269025723.md"
description: "INNOGEN-B fell over 14% after being included in the Hong Kong Stock Connect yesterday, and continued to decline this morning, with a cumulative drop of 25%. As of the time of writing, it has dropped 12.73%, trading at HKD 32.9, with a transaction volume of HKD 19.6926 million. On the news front, the Shanghai Stock Exchange and Shenzhen Stock Exchange recently announced that due to the adjustment of constituent stocks in the Hang Seng Composite MidCap Index, the list of Hong Kong Stock Connect targets has been adjusted, with INNOGEN being added to the Hong Kong Stock Connect, effective from December 8, 2025. In addition, INNOGEN announced on December 7 that its self-developed ultra-long-acting GLP-1 receptor agonist, Icosapent Ethyl α (Yinuoqing®), has officially been included in the National Medical Insurance Drug List for 2025, and will be implemented in sync with the new list starting January 1, 2026. Icosapent Ethyl α (Yinuoqing®) is a domestically produced ultra-long-acting GLP-1 receptor agonist"
datetime: "2025-12-09T03:02:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269025723.md)
  - [en](https://longbridge.com/en/news/269025723.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269025723.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/269025723.md) | [繁體中文](https://longbridge.com/zh-HK/news/269025723.md)


# Understanding the Market | INNOGEN-B fell over 12% in early trading, with a cumulative decline of 25% after "entering the market"

According to the Zhitong Finance APP, INNOGEN-B (02591) fell over 14% after being included in the Hong Kong Stock Connect yesterday, and continued to decline this morning, with a cumulative drop of 25%. As of the time of writing, it has dropped 12.73%, trading at HKD 32.9, with a transaction volume of HKD 19.6926 million.

In terms of news, the Shanghai Stock Exchange and the Shenzhen Stock Exchange recently announced that due to the adjustment of constituent stocks in the Hang Seng Composite Midcap Index, the list of Hong Kong Stock Connect targets has been adjusted, with INNOGEN being added to the Hong Kong Stock Connect, effective from December 8, 2025. In addition, on December 7, INNOGEN announced that its independently developed ultra-long-acting GLP-1 receptor agonist, Icosapent Ethyl α (Yinuo Qing®), has officially been included in the National Medical Insurance Drug List for 2025, and will be implemented in sync with the new list starting January 1, 2026. Icosapent Ethyl α (Yinuo Qing®) is a domestically produced ultra-long-acting GLP-1 receptor agonist

### 相关股票

- [INNOGEN-B (02591.HK)](https://longbridge.com/zh-CN/quote/02591.HK.md)

## 相关资讯与研究

- [Guangzhou Innogen Wins Approval to Start Trials on Pet Diabetes Drug Efsubaglutide Alfa](https://longbridge.com/zh-CN/news/274887236.md)
- [BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy | BNXTF Stock News](https://longbridge.com/zh-CN/news/280969973.md)
- [Eli Lilly: use of Foundayo with other GLP-1 receptor agonist medicines is not recommended](https://longbridge.com/zh-CN/news/281395748.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/zh-CN/news/281325910.md)
- [China's detentions of Panama-flagged vessels raise concerns, Rubio says](https://longbridge.com/zh-CN/news/281541796.md)